Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BridgeBio Pharma ( (BBIO) ) has issued an announcement.
On January 21, 2026, BridgeBio Pharma, Inc. issued $632.5 million of 0.75% Convertible Senior Notes due 2033 in a Rule 144A private placement to qualified institutional buyers, including $82.5 million issued pursuant to the initial purchasers’ option, generating approximately $619.3 million in net proceeds. The senior unsecured notes, which carry semiannual interest and are convertible into cash, common stock or a combination at BridgeBio’s election, are intended primarily to refinance or prefund a portion of the company’s 2.50% Convertible Senior Notes due 2027 and to support general corporate purposes, while maintaining pari passu ranking with BridgeBio’s existing convertible notes and extending the company’s debt maturity profile. Concurrent with the note offering’s closing on January 21, 2026, BridgeBio used about $82.5 million of cash on hand to repurchase 1,081,825 shares of its common stock in privately negotiated transactions at $76.26 per share, a move that formed part of its broader long-term debt management strategy aimed at strengthening the balance sheet, lowering interest expense, reducing dilution, and significantly extending debt maturities, with potential effects on the trading dynamics of both its stock and the new notes.
The most recent analyst rating on (BBIO) stock is a Buy with a $88.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.
Spark’s Take on BBIO Stock
According to Spark, TipRanks’ AI Analyst, BBIO is a Neutral.
BBIO scores in the mid-range: financial performance remains the biggest drag due to losses, negative equity, and declining free cash flow growth, partially offset by strong revenue growth and high gross margin. Sentiment from the latest earnings call is a key positive (Attruby commercial traction and Phase III wins), while technicals are moderately supportive but not strongly trending. Valuation provides limited help given the negative P/E and no dividend yield provided.
To see Spark’s full report on BBIO stock, click here.
More about BridgeBio Pharma
BridgeBio Pharma, Inc. is a Nasdaq-listed biopharmaceutical company focused on discovering, developing, testing and delivering transformative medicines for patients with genetic diseases. Founded in 2015, the company operates a diversified pipeline spanning early-stage research through advanced clinical trials, aiming to rapidly translate advances in genetic medicine into approved therapies.
Average Trading Volume: 2,518,238
Technical Sentiment Signal: Buy
Current Market Cap: $14.7B
See more insights into BBIO stock on TipRanks’ Stock Analysis page.